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Glaucoma filtration surgery is performed to reduce intraocular pressure (IOP) in patients for
whom maximal tolerable pharmacologic IOP-lowering therapy and/or laser surgery fail to
lower IOP sufficiently and/or fail to prevent optic nerve damage or visual field deteriora-
tion. For decades, the most widely utilized procedure for glaucoma filtration surgery has
been trabeculectomy. Although this approach reliably provides long-term IOP reduction in
many patients, the postoperative complication rate is high. This has driven the develop-
ment of alternative approaches to reduce IOP surgically. The EX-PRESS glaucoma filtration
device was developed to mimic IOP control by trabeculectomy and to have a better safety
profile. This non-valved, medical-grade stainless steel device diverts aqueous humor from
the anterior chamber to an intrascleral space. Despite the widespread use of the EX-PRESS
device, only a few studies compare its efficacy and safety with that of trabeculectomy. We
analyze available data regarding the safety and efficacy of the EX-PRESS device, particularly
in comparison with trabeculectomy.
ª 2015 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction which an opening to the anterior chamber is made so thatGlaucoma filtration surgery to reduce intraocular pressure
(IOP) when maximal tolerable pharmacologic IOP-lowering
therapy and/or laser surgery fail to lower IOP sufficiently
and/or fail to prevent optic nerve damage or visual field
deterioration16 is performedwhen the risk to vision outweighs
the risks of surgery. Since 1968, the most widely utilized pro-
cedure for glaucoma filtration surgery has been trabeculec-
tomy.3 In trabeulectomy, a partial-thickness scleral flap underCC BY-NC-ND license (ht
MD, Professor of Ophtha
, Suite 6100, Newark, NJ
Fechtner).
Authors. Published by Els
01.001aqueous humor can drain. The drained aqueous humor col-
lects within the sub-Tenon space, forming a subconjunctival
reservoir of aqueous humorda bleb. Trabeculectomy reliably
provides long-term IOP reduction in many patients. Four
years after surgery, trabeculectomy was a complete success
(IOP 18mmHgwithout IOP-loweringmedications and20%
IOP reduction) in 53% of patients and was a qualified success
(IOP  18 mm Hg with or without IOP-lowering medications
and 20% IOP reduction) in 70% of patients.17 The postoperativetp://creativecommons.org/licenses/by-nc-nd/4.0/).
lmology, Institute of Ophthalmology and Visual Science, Rutgers
07103.
evier Inc. All rights reserved.
Fig. 1 e Fornix-based under-scleral flap implantation of the
EX-PRESS P series glaucoma filtration device.
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cases, it was 47% (early complication rate), with the most
frequent being hyphema (24.6%), shallow anterior chamber
(23.9%), hypotony (24.3%), and bleb leak (17.6%). Although
most resolved within a week or two of surgery, 18.8% lost
visual acuity (>1 Snellen line), mainly from cataract devel-
opment. Additionally, 4.4% of patients suffered irreversible
visual loss.9 In a retrospective study of 301 eyes undergoing
trabeculectomy at an academic tertiary care center from 1999
to 2003, permanent vision loss occurred in 24 eyes (8.0%), 11 of
which were classified as severe (3.7%).10 The high complica-
tion rate with trabeculectomy has driven innovation in glau-
coma surgery.
The EX-PRESS glaucoma filtration device was created to
mimic trabeculectomy’s IOP control and improve its safety.
This non-valved, medical-grade stainless steel device is
approved by the U.S. Food and Drug Administration (FDA) to
divert aqueous humor from the anterior chamber to an
intrascleral space. Figure 1 shows the design of the current
P series EX-PRESS device. All EX-PRESS devices have a spur at
the proximal end and a surface plate to prevent device
intrusion into the anterior chamber. Table 1 presents key
specifications of all FDA-approved EX-PRESS models used to
date, although not all models are currently available in all
areas. Differences exist in device length, lumen size, tip shape,
shaft size, and the shape of the surface plate.Table 1 e EX-PRESS glaucoma filtration device model specifica
Model References
describing model
Lumen
diameter (mm)
Tip sha
R-50 8,18e20,23,26,31 50 Beveled
T-50 18,19 50 Round
X-50 18,23 50 Round
X-200 2,4,6,23 200 Round
P-50 1,15,23,24,30,33 50 Beveled
P-200 16,23,27 200 BeveledThe EX-PRESS devicewas initially designed to be implanted
through full-thickness sclera near the limbus directly under
the conjunctiva, thus allowing aqueous to drain into the
subconjunctival space. Early experience with this approach
demonstrated significant reductions in IOP, but high rates of
postoperative hypotony and conjunctival erosion.12,22,29,34
These complications also led to an unacceptable failure rate
of the EX-PRESS device.26,34
In 2005, Dahan and Carmichael described an alternate
surgical technique in which the device was implanted under a
scleral flap.5 This approach was associated with satisfactory
IOP control and reduced postoperative complication rates.
Most importantly, the technique reduces the risk of conjunc-
tival erosions significantly.16,27 The EX-PRESS device is
approved in most major markets globally for the treatment of
refractory cases of uncontrolled glaucomadthat is, those pa-
tients whose IOP cannot be reduced sufficiently by treatments
such as pharmacotherapy or laser surgery.
Despite the widespread use of the EX-PRESS device, a
paucity of data exist comparing its results with trabeculec-
tomy. Compared with trabeculectomy, the EX-PRESS device
eliminates the need for both peripheral iridectomy and
removal of a deep corneoscleral tissue block, but these
advantages are counterbalanced by the need to align the
device properly to avoid contact with either the cornea or the
iris. We compiled and analyzed available data regarding the
safety and efficacy of the EX-PRESS device, particularly in
comparison with trabeculectomy.2. Methods
The data extracted from the eligible studies included popu-
lation characteristics, study design, and efficacy and safety
parameters. Population characteristics were numbers of eyes
treated, diagnosis, and length of follow-up; study parameters
assessed clinical trial design (prospective/retrospective,
randomized/nonrandomized, consecutive/nonconsecutive),
treatment (EX-PRESS device implantation or trabeculectomy),
and EX-PRESS model implanted. Efficacy parameters were
mean IOP before and after treatment, mean number of
IOP-lowering medications (before and after treatment), and
success ratesdboth complete (without IOP-lowering medica-
tions) and qualified (with or without IOP-lowering medica-
tions). Safety parameters were postoperative complications,
visual acuity, and subsequent interventions. The primary
objectives of this analysis were to assess the safety andtions
pe Surface
plate shape
Length (mm) Availability
as of 2013
Uniform 2.96 Discontinued
Lateral channel 2.42 Discontinued
Lateral channel 2.42 Discontinued
Lateral channel 2.42 Discontinued
Vertically split 2.64 Available
Vertically split 2.64 Available
Fig. 2 e Process and results of identifying references for the
review.
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compare the safety and efficacy of the EX-PRESS device with
that of trabeculectomy.Table 2 e Eligible publications of EX-PRESS device single-arm
Author year
Journal
Study design Patient population
Dahan 20055
J Glaucoma
Prospective Severe open-angle glaucoma with
either previously failed filtering
surgery or high risk for failure
De Feo 20096 Can
J Ophthalmol
Prospective Medically uncontrolled glaucoma
Bissig 20102 Int
Ophthalmol
Prospective Medically uncontrolled and/or
refractory glaucoma
Gindroz 201114 Eur
J Ophthalmol
Prospective Medically uncontrolled and/or
refractory glaucoma
Gavric 201113
Coll Antropol
Prospective Primary open-angle glaucoma
or pseudoexfoliation glaucoma
Kanner 200918
J Glaucoma
Retrospective All patients treated with the
EX-PRESS implant; primarily
open-angle glaucoma
All patients treated with the
EX-PRESS implant combined
with cataract surgery; primarily
open-angle glaucoma
Lankaranian 201119
Clin Experiment
Ophthalmol
Retrospective Previous failed cataract
or glaucoma surgery3. Results
3.1. Study eligibility
A total of 57 publications were identified by the PubMed.gov
search using the terms EX-PRESS and glaucoma. Thirty-nine
publications were excluded, as shown in Figure 2, yielding a
total of 18 publications that met quality requirements for
analysis, as described in the Methods. Eligible for inclusion in
our analysis were 7 publications of 7 single-cohort studies of
EX-PRESS device implantation (or studies with all arms con-
taining EX-PRESS devices; Table 2) and 11 publications of 9
comparative studies between EX-PRESS device and trabecu-
lectomy (4 publications described different results of the same
2 studies; Table 3).3.2. EX-PRESS device single-cohort studies
3.2.1. Seminal prospective study
In the first published series where the EX-PRESS glaucoma
filtration device was implantated under a scleral flap, Dahan
and Carmichael reported on 24 eyes, 16 of which had failed
previous filtration surgery and 8 that were at high risk of
failure.5 The key result was avoidance of the late conjunctival
erosions that were common when using a subconjunctival
implantation technique.26,29,31
In that study, mean IOP reduction was >35% at all time-
points. Mean postoperative follow-up was 16.4 months, with
a maximum of 2 years. In addition, 20 of 24 eyes achieved
IOP < 21 mmHg at the last examination, with only 2 requiring
IOP-loweringmedications postoperatively. Themost common
complication was transient hypotony (21%, 5 of 24) that
resolved spontaneously. Other complications included de-
vice iris touch (12.5%, 3 of 24), of which 1 case requiredstudies
Intra-operative
mitomycin C?
EX-PRESS model
implanted
Eyes (N) Follow-up
(months)
Yes R-50 24 16.4
Yes R-50, T-50, or X-50 37 18
If at risk for
fibrosis (n ¼ 23)
X-200 26 18.6  2.4
If at risk for
fibrosis (n ¼ 22)
R-50 24 40.1  10.8
Yes unknown 44 8.6  7.5
Yes R-50, T-50, or X-50 231 25.7  11.1
Yes X-200 114 21.9  12.5
Yes R-50 or T-50 100 27  13.2
Table 3 e Eligible publications of EX-PRESS device versus trabeculectomy studies
Author year Journal Study design Patient population EX-PRESS model implanted or
trabeculectomy
Eyes (N) Mean
Follow-up
(months)
Dahan 20124 Eye Prospective, randomized, fellow-eye Medically uncontrolled primary
open-angle glaucoma
X-200 15 23.6  6.9
Trabeculectomy 15
de Jong 20097 Adv Ther Prospective, randomized, parallel-
group
Uncontrolled open-angle glaucoma; did
not have previous ocular surgery (except
cataract surgery)
R-50 40 11.6  2.1
Trabeculectomy 40
de Jong 20118 Clin Ophthalmol 5-year update of above trial Uncontrolled open-angle glaucoma; did
not have previous ocular surgery (except
cataract surgery)
R-50 39 60.6  0.9
Trabeculectomy 39 61.3  3.2
Beltran-Agullo 20131 Wagschal
201333 J Glaucoma
Prospective, randomized, controlled Uncontrolled open-angle glaucoma and
trabeculectomy as planned procedure
P-50
Trabeculectomy
64 12
Netland 201424 Am J Ophthalmol Prospective, randomized, comparative Open-angle glaucoma, history of laser
trabeculoplasty or cataract
phacoemulsion at least 2 months prior
to study.
P-50
Trabeculectomy
120 24
Gallego-Pinazo 200911 Arch Soc
Esp Oftalmol
Prospective, case control Uncontrolled open-angle glaucoma; did
not have previous glaucoma surgery;
exhibited a decrease in vision associated
with cataracts and glaucomaa
R-50 þ cataract surgery 20 9.7
Trabeculectomy þ cataract surgery 20 10.3
Good 201115 Am J Ophthalmol Retrospective, case control Uncontrolled glaucoma P-50 35 28  3.2
Trabeculectomy 35
Maris 200720 J Glaucoma Retrospective, case control Uncontrolled glaucoma; most did not
have previous glaucoma surgery
R-50 (þcataract surgery [n ¼ 15]) 50 10.8  3.1
Trabeculectomy (þcataract surgery [n ¼ 15]) 50 11.2  3.1
Marzette 201121 Ophthalmic Surg
Lasers Imaging
Retrospective, case control Uncontrolled glaucoma despite maximal
medical therapy or failed previous
glaucoma surgery
X-50 and X-200 (þcataract surgery [n ¼ 19]) 76 9.1  3.5
Trabeculectomy (þcataract surgery [n ¼ 20]) 77 9.2  4.9
Sugiyama 201130 Clin Ophthalmol Retrospective, case control Japanese
patients
Open-angle glaucoma; some had previous
intraocular surgery
P-50 (þcataract surgery [n ¼ 3]) 10 NR
Trabeculectomy (þcataract surgery [n ¼ 3]) 11 NR
NR, not reported.
a This study did not provide surgical details, but all other studies in this table reported that they used intraoperative mitomycin C.
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resolved spontaneously; hyphema (8%, 2 of 24), of which 1
case required anterior chamber washout; and a single case of
shallow anterior chamber requiring reformation (4%).
3.2.2. Additional prospective studies
Five additional prospective single-cohort studies examine
EX-PRESS device implantation (Table 4). The Dahan et al5
series had 24 eyes in which the EX-PRESS device was
implanted under a scleral flap instead of under the conjunc-
tiva. De Feo and colleagues6 had 37 consecutive eyes where
the EX-PRESS device was used as primary therapy for medi-
cally uncontrolled primary open-angle glaucoma. Gindroz and
colleagues collected 24 nonconsecutive eyes treated with the
EX-PRESS device as part of combined filtering and cataract
surgery.14 The Bissig and colleagues2 series had 26 noncon-
secutive eyes, 20 of which were refractory to previous glau-
coma surgery. Gavric and colleagues13 reported on 44 eyes
from 35 patients; 21 had primary open-angle glaucoma and 14
had pseudoexfoliation glaucoma. In the Gindroz and Bissig
studies, a modified deep sclerectomy was performed, aiming
to create an intrascleral bleb, in addition to the scleral flap
implantation of the EX-PRESS device.
Dahan et al found the EX-PRESS device to be safe when
implanted under a scleral flap.5 There was a 45.1% reduction
in IOP at 24 months (P ¼ 0.016). Complications included
hyphema (8.3%), transient hypotony (20.8%), transient cho-
roidal effusions (8.3%), device iris touch (12.5%), and shallow
anterior chamber (4.1%).
De Feo and colleagues used the X-200 EX-PRESSmodel with
a mean follow-up period of 18 months.6 They acheived com-
plete success (defined as IOP< 18mmHg and no IOP-lowering
medications) in 78% (29 of 37 eyes). An additional two eyes
(5%, 2 of 37) were a qualified success (IOP < 18 mm Hg when
treated with two IOP-lowering medications). Eyes achieved a
mean IOP reduction of 55%. Complications included serous
choroidal detachment (24%, 9 of 37), of which 6 cases were
treated with viscoelastic injection into the anterior chamber,
and transient hypotony at 1 day (32%, 12 of 37) and at
1week (22%, 8 of 37). In one case, transconjunctival suturing of
the scleral flap was required because of persistent hypotony
and chronic choroidal detachment. There were no sight-
threatening consequences.
Gavric and colleagues implanted the EX-PRESS device
under a scleral flap in patients with medically uncontrolled
glaucomawho had previously undergone glaucoma surgery.13
This reduced IOP of the 44 eyes by 53% at 1 year (P < 0.001). In
addition, mean number of IOP-lowering medications used per
patient decreased 77%. They had seven early postoperative
complications: a case of hypotony, two cases of hypotonywith
choroidal detachment, a case of intraocular hemorrhage, and
a case of shunt closure. All successfully resolved.
Gindroz and colleagues studied implantation of the R-50
model using modified deep sclerectomy during cataract
surgery for patients with medically uncontrolled glaucoma
undergoing phacoemulsification and intraocular lens im-
plantation.14 Most of the 24 eyes had open-angle glaucoma
(two had angle-closure glaucoma, and three had secondary
glaucoma). Five had previously undergone glaucoma surgery.
Intraocular pressure was reduced by more than 25% at 24 and48months (mean follow-up of 40.1months). In addition,mean
number of IOP-lowering medications used decreased 74%
(from 2.3 to 0.6 medications) at last follow-up. At 48 months,
the complete success rate (defined as IOP > 6 mm Hg and
18 mm Hg without IOP-lowering medication), as calculated
by a Kaplan-Meier survival curve, was 46% and the qualified
success rate (with or without IOP-lowering medication) was
85%. There were two major complications: a case of endoph-
thalmitis ending in phthisis bulbi, and a case of device clotting
by fibrin deposits resolved with classic deep sclerectomy and
mitomycin C injection. Other complications included poste-
rior capsule opacification (54%, 13 of 24), cystic bleb/no bleb
(21%, 5 of 24), IOP spikes within the first month (17%, 4 of 24),
bleb leak (13%, 3 of 24), hyphema (8%, 2 of 24), flat anterior
chamber (8%, 2 of 24), choroidal effusion (8%, 2 of 24), and
single cases of contact between device and cornea, macular
edema, and retinal branch vein occlusion.
Bissig and colleagues examined the implantation of the
X-200 EX-PRESSmodel under a scleral flap in conjunctionwith
amodified deep sclerectomy in 26 patients,most of whomhad
open-angle glaucoma. Two had uveitic glaucoma and one
each has traumatic glaucoma, angle-closure glaucoma, and
secondary glaucoma.2 Their technique involved not only a
routine scleral flap, but also a deep dissection of the sclera
posterior to the EX-PRESS device. They aimed for a removal of
a block of sclera up to 98% of the sclera depth. They felt that
this facilitated suprachoroidal filtration in addition to sub-
conjunctival filtration. They found that mean IOP reduction
was >42% at all times measured over 18 months (mean
follow-up was 18.6  2.4 months). In addition, mean number
of IOP-lowering medications decreased by 79% (P < 0.001) at
18 months after implantation. The complete success rate (IOP
> 6mmHg and18mmHgwithout IOP-loweringmedication)
at the last follow up visit based on Kaplan-Meier analysis
was 69% and the qualified success rate (same IOP criteria with
or without medication) was 85%. The most common compli-
cation was an encysted bleb (54%, 14 of 26), 10 of which
responded to needling. Transient hypotony, hyphema, and
bleb leak each developed in 4 eyes (15% prevalence each
event), and shallow anterior chamber and blebs fibrosis each
occurred in 2 eyes (8% prevalence each event).
3.2.3. Retrospective studies
The remaining two single-cohort studies examining EX-PRESS
device implantation were retrospective case series (Table 5).
Lankaranian and colleagues19 had 100 previously operated
eyes (glaucoma surgery, n ¼ 48; cataract extraction, n ¼ 50;
other, n ¼ 2). Kanner and colleagues18 had 345 eyes conse-
cutively implanted with EX-PRESS devices with or without
concomitant cataract surgery.
Lankaranian and colleagues implanted R-50 models in 84
cases and T-50 models in 16 and then followed patients for a
mean of 27  13.2 months.19 Mean IOP reduction was 49% at
last follow-up (P < 0.0001 versus baseline). In addition, mean
number of IOP-lowering medications used decreased 74% at
last follow-up (P < 0.0001). Kaplan-Meier analysis of the
probability of complete success (defined as IOP 5mmHg and
21 mm Hg without IOP-lowering medication) was 80% at
1 year, 64% at 2 years, and 56% at 3 years. The probability of
qualified success (IOP  5 mm Hg and 21 mm Hg with or
Table 4 e Summary results of EX-PRESS device prospective single-arm studies
Author year
Journal
Eyes (N) Surgery
type
Follow-up
(months)
Complete success rate
(no IOP-lowering
medication)
Qualified success
rate (with/without
IOP-lowering
medication)
Mean IOP
reduction
Reduction in
number of
IOP-lowering
medications
Complications
Dahan 20054 24 S 24 NR NR 45.1% (P ¼ 0.016) NR Hyphema (8.3%)
Transient hypotony (20.8%)
Transient choroidal effusions (8.3%)
Device iris touch (12.5%)
Shallow anterior chamber (4.1%)
De Feo 20096 Can
J Ophthalmol
37 S 18 78% (29 eyes) at
last follow-up
(IOP < 18 mm Hg)
84% (31 eyes) at
last follow-up
(IOP < 18 mm Hg)
55% at last
follow-up
NR Transient hypotony at 1 day (32%)
Serous choroidal detachment (24%)
Transient hypotony at 1 week (22%)
Bissig 20102 Int
Ophthalmol
26 S 18.6  2.4 69% at last follow-up
(IOP > 6 mm Hg
and 18 mm Hg)
85% at last follow-up
(IOP > 6 mm Hg
and 18 mm Hg)
>42% at all time
points measured
through 18 months
79% (P < 0.001)
at 18 months
Encysted bleb (54%)
Bleb leak (15%)
Hyphema (15%)
Transient hypotony (15%)
Blebs fibrosis (8%)
Shallow anterior chamber (8%)
Gindroz 201114
Eur J Ophthalmo
24 C 40.1  10.8 46% at 48 months
(IOP > 6 mm Hg
and 18 mm Hg)
85% at 48 months
(IOP > 6 mm Hg
and 18 mm Hg)
>25% at 24 and
48 months
74% (P < 0.05) at
last follow-up
Posterior capsule opacity (54%)
Cystic bleb/no bleb (21%)
IOP spikes within first month (17%)
Bleb leak (13%)
Choroidal effusion (8%)
Flat anterior chamber (8%)
Hyphema (8%)
Contact between device and cornea (4%)
Device clotting (4%)
Endophthalmitis (4%)
Macular edema (4%)
Retinal branch vein occlusion (4%)
Gavric 201113
Coll Antropol
44 S 8.6  7.5 NR NR 53% at 1 year
(P < 0.001)
77% reduction
at 1 year
Hypotony with choroidal detachment (7%)
Hypotony (4%)
Intraocular hemorrhage (4%)
Postoperative shunt closure (4%)
NR, not reported; S, stand-alone surgery; C, combined with cataract surgery.
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was 94%, 77.5%, and 67%, respectively. Sixteen eyes failed to
respond sufficiently to EX-PRESS device implantation. Unlike
most other studies examined in this analysis, a requirement
for bleb needling (n ¼ 4 eyes) was considered an insufficient
response. Postoperative complications were conjunctival
leakage requiring contact lens (3%, 3 of 100) or conjunctival
resuturing (3%, 3 of 100), hyphema requiring medical therapy
(2%, 2 of 100), and single cases of choroidal detachment
requiring medical therapy or choroidal drainage and wound
gap requiring surgical repair.
Although not technically a single-cohort study, Kanner and
colleagues conducted a retrospective, comparative case series
in which both arms received EX-PRESS device implantation. A
total of 231 eyes were treated only with the R-50, T-50, or X-50
EX-PRESS device and were followed for 25.7  11.1 months,
and 114 cataractous eyes were treated with these same
EX-PRESS device models combined with phacoemulsification
and were followed for 21.9  12.5 months.18 Mean IOP reduc-
tion of the non-cataractous group was statistically significant
versus baseline at each time point (P< 0.05), ranging from 41%
to 54% reductions. Thiswas also true for the combined surgery
group (P< 0.05), ranging from 20% to 35% reductions, except at
30 months where P ¼ 0.16 and reduction was 11%. Mean
number of IOP-lowering medications was significantly
reduced at 42months in both treatment groups (P< 0.05), with
medication numbers decreasing by 69% in the non-
cataractous group and by 73% in the combined surgery
group. Kaplan-Meier analysis of the probability of qualified
success (defined as IOP  5 mm Hg and 21 mm Hg with or
without IOP-lowering medication, without requiring further
surgery, andwithout total loss of vision) at 3 years was 95% for
the non-cataractous group and 96% for the combined surgery
group. Postoperative complications in the non-cataractous
group were hypotony in the first week (16%, 36 of 231); bleb
leak (5%, 12 of 231); and single cases of blocked tube resolved
by Nd:YAG laser treatment, exposed implant dislocated
implant, and dysesthetic bleb. Postoperative complications in
the combined therapy group included hypotony in the first
week (8%, 9 of 114), bleb leak (4%, 5 of 114), blocked tube
resolved by Nd:YAG laser treatment (3%, 3 of 114), and single
cases of choroidal hemorrhage and aqueous misdirection.
3.3. EX-PRESS device versus trabeculectomy studies
Tables 6e12 present the compiled data from the nine publi-
cations (of eight studies) comparing EX-PRESS device with
trabeculectomy.
3.3.1. Randomized studies
Four of the nine comparative studieswere randomized. Dahan
and colleagues4 and de Jong7 first published results after 1 year
of follow-up and then after 5 years of follow-up.8 Beltran-
Agullo and colleagues (with a 1-year follow-up by Wagschal
et al) and Netland et al have recently found differences in vi-
sual recovery rates between the two procedures.1,24,33
Dahan and colleagues conducted a randomized, fellow-eye
study of 15 patients with medically uncontrolled primary
open-angle glaucomawho had trabeculectomy in one eye and
the EX-PRESS X-200 implanted device in the fellow eye.4
Table 6 e Mean IOP values from EX-PRESS device versus trabeculectomy studies
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Table 7 e Success rates from EX-PRESS device versus trabeculectomy studies
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Table 8 e Need for IOP-lowering medications from EX-PRESS device versus trabeculectomy studies
s u r v e y o f o p h t h a lmo l o g y 6 0 ( 2 0 1 5 ) 3 2 7e3 4 5336Baseline glaucoma severity and baseline IOP were similar in
both groups. Both treatment groups demonstrated significant
IOP decreases from baseline (both P < 0.001) at last follow-up–
48% for the trabeculectomy group and 44% for the device
group. Similarly, both groups had significant decreases versus
baseline (both P < 0.001) in the mean number of IOP-lowering
medications at last follow-upda 2.8-unit decrease for the
trabeculectomy group and a 3.4-unit decrease for the deviceTable 9 e Early postoperative hypotony rates from EX-PRESS dgroup. The eyes receiving device implantation had a signi-
ficantly higher probability (P ¼ 0.002) of complete success
(defined as 5e18 mm Hg with no IOP-lowering medications)
and of qualified success (P¼ 0.01; 5e18mmHgwith or without
IOP-lowering medications).
The device group from the Dahan study had a lower rate of
eyes with one or more postoperative complication (20% [3 of
15] vs 33% [5 of 15]; P ¼ 0.05). These were shallow anteriorevice versus trabeculectomy studies
Table 10 e Other (non-hypotony) postoperative complications from EX-PRESS device versus trabeculectomy studies
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high avascular bleb. The device group also had a lower rate of
eyes with one or more postoperative interventions required
(0% vs 27% [4 of 15]; P ¼ 0.0009). These interventions were bleb
excision and anterior chamber reformation or decompression.
Postoperative visual acuity in both groups remained stable
compared with preoperative values.
de Jong reported on 80 eyes of 78 patients with open-angle
glaucoma not controlled with medical therapy that were
randomized to receive either the EX-PRESS R-50 device or
trabeculectomy.8 All baseline demographics were similar
between groups, except mean age, which was lower in the
device group than in the trabeculectomy group (62.3  14.5
years vs 68.9  11.5 years, P ¼ 0.03).7 After a mean post-
operative follow-up of 11.6 months, the mean IOP reduction
was 42% in the device group and 29% in the trabeculectomy
group (P ¼ 0.05).7 Significant differences in mean IOP favoring
the device group were present at year 1 (P ¼ 0.02), year 2 (P ¼
0.01), and year 3 (P ¼ 0.04), but not at years 4 or 5. When IOP
was adjusted for patient age, these P values were slightly less
favorable (P ¼ 0.05, P ¼ 0.01, P ¼ 0.08, respectively).8 No sig-
nificant differences between groups were observed in the
mean number of IOP-lowering medications,7,8 although fewer
patients in the device group used IOP-loweringmedications at
each time point, ranging from 13% (5 of 39) at 1 year to 41%
(16 of 39) at 5 years. In comparison, 36% (14 of 39) of patients
treated with trabeculectomy used IOP-lowering medications
at 1 year, which rose to 54% (21 of 39) at 5 years.8 After
12 months of follow-up, significantly more patients in the
device group achieved complete success (here defined as
18mmHgwith no IOP-lowering medications) than did those
in the trabeculectomy group (85% [33 of 39] vs 60% [24 of 40];
P ¼ 0.02).7 This statistically significant advantage was main-
tained through 3 years of follow-up, with 67% (26 of 39) of the
device group achieving complete success, compared with 41%
(16 of 39) of the trabeculectomy group. At years 4 and 5 the
differences were no longer significant.8 Qualified success
(18 mm Hg with or without IOP-lowering medications) was
similar between groups after 12 months of follow-up,7 and at
each time point from year 2 through year 5.8
None of the postoperative complication rates (shallow
or flat anterior chamber, bleb leak, choroidal detachment,
hyphema, IOP spike, and hypotony) reported by de Jong were
significantly different between groups;7 the author concluded,
however, that the hypotony ratewith device implantationwas
artificially high because of the learning curve of the surgeon.
The first 11 patients receiving the device had a higher rate of
hypotony compared with the remaining patients. Although
specific subsequent interventions (needling, laser suture lysis,
bleb revision, etc.) were also similar between groups, the de-
vice group underwent fewer total interventions than the tra-
beculectomy group (3 vs 8).7 Visual acuity at 12 months was
unchanged or improved in themajority of patients in both the
device group (86%, 32 of 37) and the trabeculectomy group
(84%, 32 of 38). The remaining patients, five in the device group
and six in the trabeculectomy group, showed a decline in
visual acuity.
Recovery of visual acuity (VA) was assessed by Beltran-
Agullo et al1 and Wagschal et al33 at 6 months and 1 year,
respectively. This study compared 33 EX-PRESS device-treated
Table 11 e Subsequent interventions from EX-PRESS device versus trabeculectomy studies
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Table 12 e Postoperative visual acuity from EX-PRESS device versus trabeculectomy studies
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total enrolled.31 Patients with uncontrolled IOP on maximum
tolerated medication and trabeculectomy as the planned
surgical procedure were included in this randomized,
controlled trial. There was no difference in VA between the
study groups at baseline. There was also a similar number of
pseudophakic eyes in both groups (42%). They evaluated
postoperative changes in VA and risk factors for visual loss.
Although the initial negative impact on VA was similar be-
tween the two groups, VA in a significant number of patients
in the EX-PRESS-device group returned to baseline within
1 month post surgery and remained stable for the one year
duration of the study. In contrast, VA in the trabeculectomy
group was significantly lower than baseline throughout the
study (P < 0.001). Loss of VA 2 Snellen lines occurred in 47%
of patients at 6 months and 30% of patients at 1 year in the
trabeculectomy group, as compared with 16% of patients at
6months and 3% of patients in the EX-PRESS device group (P¼
0.01 at 6 months and P ¼ 0.006 at 1 year). The causes of visual
loss were similar in the two groups. Hypotony occurred in
about 45%. Shallow or flat anterior chamber, choroidal effu-
sion, wound leak, hyphema, encapsulated bleb, iritis, and
cataract were other causes. There were no predictable risk
factors among the ones evaluated (split fixation, cup-to-disk
ratio, preoperative IOP, Humphrey Visual Field mean devia-
tion, IOP at all postoperative intervals, and lens status). In
conclusion, although IOP-lowering efficacy was similar be-
tween the two procedures, use of the EX-PRESS device led to
faster VA recovery than after trabeculectomy.
Similar to the previous observations, Netland et al
observed lower complication rates with the EX-PRESS device
than with trabeculectomy (P ¼ 0.013) in a randomized com-
parative trial of EX-PRESS device versus trabeculectomy, with
follow-up up to 2 years post surgery.24 Themain postoperative
complications were shallow anterior chamber and choroidal
effusion, cataract, hyphema, wound leaks, and endoph-
thalmitis. Specifically, they found recovery of visual acuity to
baseline occurred within 1 month in the EX-PRESS device
group (0.3 vs 0.28 logMAR) as compared with 3 months in the
trabeculectomy group (0.25 vs 0.37 logMAR). The two groups
being compared included 59 eyes treated with EX-PRESS
and 61 eyes treated with trabeculectomy. Both groups
demonstrated a significant decrease from baseline in mean
IOP (P < 0.001), at 2 years post surgery. Additionally, there was
a 71% and 77% drop in medications required in the EX-PRESS
and trabeculectomy groups, respectively (P < 0.001). Surgical
success was 83% and 79% 2 years after surgery, and the reason
for failure was increased IOP.
3.3.2. Case-control studies
Gallego-Pinazo and colleagues11 describe a prospective, con-
secutive, case-control series comparing EX-PRESS device
implantation with trabeculectomy. Eligible patients had un-
controlled open-angle glaucoma and needed cataract surgery.
Twenty eyes received combined cataract surgery and glau-
coma surgery using the EX-PRESS implant, and 20 eyes
received combined cataract surgery and trabeculectomy. No
significant differences were observed between groups in
complete success rate (here defined as IOP > 5 mm Hg and
<21 mm Hg without IOP-lowering medication or surgicalinterventions). In order to reach target IOP, one or more
medications were required by 10% (2 of 20) of eyes in the de-
vice group and 20% (4 of 20) of eyes in the trabeculectomy
group. No postoperative complications occurred in the device
group, but the trabeculectomy group experienced hypotony
(shallow anterior chamber; 30%, 6 of 20), hyphema (40%, 8 of
20), and choroidal detachment (15%, 3 of 20). Twenty percent
(4 of 20) of eyes in the device group required needling and 10%
(2 of 20) required laser suture lysis. Fifteen percent (3 of 20) of
eyes receiving trabeculectomy also required laser suture lysis.
There are four additional retrospective, consecutive,
case-control series comparing EX-PRESS device implantation
with trabeculectomy: Good and colleagues,15 Maris and
colleagues,20 Marzette and colleagues,21 and Sugiyama and
colleagues.30
Good and colleagues conducted a case series of 70 patients,
most with open-angle glaucoma, but 10 with angle-closure
glaucoma. In that study, 35 patients received EX-PRESS de-
vice implantation and 35 underwent trabeculectomy.15 In
addition to the more traditional postoperative measures of
IOPdreduction of need for IOP-lowering medication, success
rates, and complication ratesdinvestigators also quantified
less common parameters such as time to restoration of vision
to baseline level and number of postoperative visits in the first
3 months. They also made a novel assessment of bleb
morphological features. During a follow-up of 28  3 months,
the device group had higher mean absolute IOP at 1 year (P ¼
0.004) and at last follow-up (P ¼ 0.008), but the relative IOP
reductions from preoperative to last follow-up were similar
between the device (45%) and the trabeculectomy groups
(48%). Complete success rates (defined as IOP between 5 mm
Hg and 18 mm Hg and 30% decrease in IOP without IOP-
lowering medications) were similar between groups, with
77% (27 of 35) reported from the device group and 74% (26 of
35) reported from the trabeculectomy group. Qualified success
rates (same IOP requirements, regardless of IOP-lowering
medication use) were also similar, with an additional 6%
(2 of 35) of eyes in the device group and 9% (3 of 35) in the
trabeculectomy group achieving target IOP with the use of
pharmacologic therapy. The mean number of medications
was similar between the two groups, both preoperatively
(2.3  0.8 for both) and at the last follow-up (0.15  0.35 in the
device group, 0.2  0.4 in the trabeculectomy group).
Complication rates reported by Good et al were lower in the
device group, but not significantly different from the trabe-
culectomy group, with fewer cases of early postoperative
hypotony (2 vs 5) and hyphema (1 vs 4) compared with the
trabeculectomy group. Mean corrected distance visual acuity
worsened slightly at 1 day after surgery in both groups, then
returned to baseline values at the 1 week visit for the device
group, but not until the 1 month visit for the trabeculectomy
group. Mean visual acuity was statistically similar between
groups at all timepoints except at the 1 week visit, when the
device group demonstrated significantly better visual acuity
than the trabeculectomy group (P ¼ 0.03).
In the novel findings regarding bleb morphology, in-
vestigators reported that device group blebswere less vascular
than blebs from the trabeculectomy eyes, but no differences in
bleb vascularity were apparent by the last visit (average
follow-up ¼ 28 months). Bleb height was lower in the device
s u r v e y o f o p h t h a lmo l o g y 6 0 ( 2 0 1 5 ) 3 2 7e3 4 5342group in the early postoperative period of up to 3 months of
follow-up and higher from 6 to 18 months of follow-up, but
these differences disappeared by the last visit. Device group
blebs were also more diffuse than those from the trabeculec-
tomy group from 3 months to 18 months of follow-up, but
these differences also disappeared. Patients in the device
group required fewer postoperative visits within the first
3 months compared with the trabeculectomy group (6 vs 8,
P < 0.001).
Maris and colleagues conducted a case series of 100
eyesdmost with open-angle glaucoma, but 9 with combined
mechanism glaucoma, 3 with angle-closure glaucoma, 4 with
uvieitic glaucoma, and 1 with iridocorneal-endothelial syn-
drome. A total of 50 each received EX-PRESS device implan-
tation or trabeculectomy.20 Eligible eyes had uncontrolled
glaucoma while on maximal tolerable IOP-lowering therapy,
and nearly all (97 of 100) had not undergone previous glau-
coma surgery. Fifteen patients from each group had cataract
surgery performed in conjunctionwith device implantation or
trabeculectomy. During a mean follow-up period of approxi-
mately 11months, the two groups had similarmean IOPs from
6 months through 15 months postoperatively. Change from
baseline IOP was also similar between groups at those time
points. Those patients who received simultaneous cataract
surgery had significantly lower preoperative mean IOP than
those who only received device implantation (P ¼ 0.006) or
trabeculectomy (P ¼ 0.02), but cataract surgery did not
significantly impact postoperative mean IOP or complete
success rate. Qualified success rates (defined as IOP  5 mm
Hg and 21 mmHg with or without IOP-lowering medications
and without further glaucoma surgery) were 98% and 96% at
6 months, and 86% and 84% at 15 months in the device and
trabeculectomy groups, respectively. Complete success rates
were not reported. Five eyes from the device group and four
from the trabeculectomy group were not sufficiently respon-
sive to surgery.
Two complications occurred significantly less frequently in
the device group than in the trabeculectomy group: hypotony
(4%, 2 of 50 vs 32%, 16 of 50; P < 0.001) and choroidal effusion
(8%, 4 of 50 vs 38%, 19 of 50; P < 0.001). All other complications
(flat anterior chamber, hypotony maculopathy, hyphema,
bleb leak, and endophthalmitis) were similar between groups.
Significantly more laser suture lysis procedures were neces-
sary to control IOP in device-implanted eyes than in trabecu-
lectomized eyes (a mean of 2.2  1.1 procedures vs 1.7  1.5
procedures; P< 0.01). These higher-than-expected suture lysis
procedure rates indicate a conservative approach to insert
tight sutures in both treatment groups to reduce the risk of
hypotony since the EX-PRESS device was a novel intervention
at the time (personal communication, Peter Netland and
Peter Maris). The number of bleb needling procedures with
5-fluorouracil was similar between groups (10 in the device
group; 7 in the trabeculectomy group). At last visit, post-
operative visual acuity changes were similar between groups,
with 80% (40 of 50) of eyes in the device group and 84% (42 of
50) of eyes in the trabeculectomy group maintaining or
improving visual acuity.
Marzette and colleagues studied 153 eyes, most with open-
angle glaucoma. Eleven had combined mechanism glau-
coma, three each with angle-closure glaucoma and uveiticglaucoma; and one with traumatic glaucoma. A total of 76
received EX-PRESS device implantation, and 77 underwent
trabeculectomy.21 Eligible eyes had uncontrolled glaucoma
while on maximally tolerated IOP-lowering therapy or after
previous glaucoma surgery (n ¼ 40, device group; n ¼ 47,
trabeculectomy group). After a mean follow-up of approxi-
mately 9 months, mean IOP was similar between groups. The
change from baseline IOP was also similar. Nineteen eyes in
the device group and 20 eyes in the trabeculectomy group had
concurrent cataract surgery. At all time points, the mean IOP
of the device group undergoing concurrent cataract surgery
was similar (P  0.32) to the group receiving the device alone.
Eyes in the device group had a mean of 3  1.2 preoperative
IOP-lowering medications compared with 2.6  1.1 in the
trabeculectomy group (P ¼ 0.06). Although the mean post-
operative number of medications was similar between groups
(0.4  0.9 vs 0.5  1.1), the change in number of medications
favored the device group (2.6  1.5 vs 2.1  1.4, P ¼
0.02).When patients in the device group were divided and
analyzed by whether they underwent simultaneous cataract
surgery, no significant difference was observed between pre-
operative or postoperative mean IOP in patients who received
device implantation. Patients in the trabeculectomy group
who also received phacoemulsification had higher post-
operative mean IOP at postoperative day 1 through month 1,
but no significant difference in IOP at the last visit. Complete
success rates (defined as IOP  5 mm Hg and 21 mm Hg and
without further glaucoma surgery) were 70% (53 of 76) for the
device group and 53% (41 of 77) for the trabeculectomy group,
which did not reach statistical significance (P ¼ 0.09). An
additional 9 eyes (12%) from the device group and 14 eyes
from the trabeculectomy group (18%) were qualified suc-
cesses. Fourteen eyes from the device group and 22 from
the trabeculectomy group were not sufficiently responsive to
surgery.
Significantly fewer (P < 0.05) eyes experienced hypotony in
the device group (4%, 3 of 76) than the trabeculectomy group
(14%, 11 of 77). All other complications (bleb leak, shallow
anterior chamber, choroidal effusion, hypotony, maculop-
athy, and hyphema) were similar between groups. No signif-
icant difference was observed in the number of laser suture
lysis procedures performed between groups (n ¼ 34, device
group; n ¼ 41, trabeculectomy group), in the number of times
5-fluorouracil was administered (n ¼ 2 each group), or in the
number of times bleb needling was performed (n ¼ 1 each
group).
Sugiyama and colleagues conducted a pilot case series of
21 eyes of Japanese patients with open-angle glaucoma, with
10 eyes receiving EX-PRESS device implantation and 11 un-
dergoing trabeculectomy.30 Three eyes in each group had
concurrent cataract surgery. Mean IOP was similar between
groups at 6, 9, and 12 months postoperatively. At a follow-up
of 1 year, qualified success rates (defined as IOP  5 mm Hg
and21mmHg at 1-, 3-, 6-, 9-, and 12-month time points with
or without IOP-lowering medications and without further
glaucoma surgery or total loss of vision) were 100% (10 of 10)
for the device group and 82% (9 of 11) for the trabeculectomy
group. The difference did not reach statistical significance (P¼
0.17). At 1 year after surgery, eyes in the device group required
a numerically, but not significantly (P ¼ 0.11), lower mean
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with the trabeculectomy group (1.4  1.2).
No significant differences were observed between groups
for any of the reported complications: shallow anterior
chamber, hypotony, choroidal detachment, hyphema, bleb
leak, endophthalmitis, fall in visual acuity by 2 or more deci-
mal levels, or glaucoma progression; however, both reduced
visual acuity (1 out of 10 cases in the EX-PRESS group vs 5 out
of 11 cases in the trabeculectomy group) and visual field defect
progression (none in the EX-PRESS group vs 4 out of 11 cases in
the trabeculectomy group) showed a tendency favoring the
device group (P ¼ 0.15 and P ¼ 0.09, respectively). No signifi-
cant difference was observed in the number of laser suture
lysis procedures performed between groups (30% [3 of 10] in
the device group, 64% [7 of 11] in the trabeculectomy group) or
in the number of times bleb needlingwas performed (20% [2 of
10] in the device group, 33% [3 of 11] in the trabeculectomy
group). Mean visual acuity was relatively stable in the device
group, and only 1 of 10 eyes experienced a decline in visual
acuity of 2 or more decimal levels. In contrast, 5 of 11 eyes
exhibited a 2-decimal level or greater decline in visual acuity
in the trabeculectomy group, and mean visual acuity was
significantly lower than preoperative visual acuity from
1 week through 3 months in this group.4. Discussion
Of the four randomized prospective studies comparing
IOP-lowering efficacy of the EX-PRESS device with trabecu-
lectomy, only one demonstrated lower long-term IOP with
EX-PRESS device implantation.1,4,7,8,24,33 In that study, there
was a significant difference inmean IOP between groups up to
3 years, but this difference was no longer significant at years 4
and 5 of follow-up.7,8 Neither the prospective, nonrandomized
study11 nor most of the four additional retrospective tri-
als20,21,30 reviewed showed a significant difference in IOP be-
tween groups, although one study observed higher IOP in the
device group at 1 year and at last follow-up.15 Overall, glau-
coma surgery with the EX-PRESS device achieves IOP reduc-
tion similar to that of trabeculectomy. It remains unclear
whether there is any long-term, clinically relevant superiority
in mean IOP reduction with either technique.
Two of the four randomized studies4,7,8 showed higher
complete success rates (using 18 mm Hg as the cutoff) with
device implantation than with trabeculectomy, and one of
them4 showed a superior qualified success rate as well. None
of the nonrandomized studies demonstrated a significant
difference in success rates between groups.11,15,20,21,30 In most
of these studies, the need for suture lysis or needling was not
considered treatment failure. The definition of success varied
across studies, from 18 mm Hg to <21 mm Hg, making
it difficult to compare rates across studies; however, these
varying definitions do not invalidate the relevance of com-
paring the relative success rates of trabeculectomy and
EX-PRESS implantation within these studies.
None of the clinical trials, including three of the four
randomized studies,1,4,7,8,24,33 demonstrated a significan-
tly different mean number of IOP-lowering medications
used between groups,15,20,21,30 although one showed a greaterreduction in the need for such medications favoring the de-
vice group.21 Currently, there is little evidence supporting a
difference in the number of IOP-lowering medications needed
postoperatively.
Of the two randomized trials, one showed an apparent
superiority in the hypotony rate for the device group (7% vs
33%, P ¼ 0.05),4 while the other showed no significant differ-
ence between groups.7 Both rates in the second randomized
trial were relatively high (16% vs 22%), possibly because no
intraoperative viscoelastic was used.6,7 Furthermore, the
authors felt that their learning curve for the EX-PRESS device
implantation elevated the hypotony rate of the device group.
A third randomized clinical trial concluded that early hypot-
ony was the most common complication, but there were no
differences in the device and trabeculectomy arms.1 Themost
recent randomized trial did not report hypotony as a post-
operative complication at 2 years post surgery.24 Two of the
four nonrandomized studies showed a significantly lower rate
of hypotony with EX-PRESS device implantation,20,21 and the
other two showed no significant difference.15,30 The remain-
ing study did not report hypotony rates.11 Postoperative
hypotony is highly sensitive to surgical technique, but it ap-
pears that the EX-PRESS device does not pose any increased
risk for hypotony after the initial learning curve andmay have
some advantage, depending on surgical technique.
Two of the randomized trials reported a lower overall
postoperative complication rate with EX-PRESS device im-
plantation (P ¼ 0.05 and 0.013)4,24 and another showed no
significant differences in any of the individual postoperative
complication rates.7 Two randomized trials also showed
significantly better1,33 or faster24 recovery from loss of visual
acuity in the EX-PRESS device group as compared to the tra-
beculectomy group. In the prospective, nonrandomized study,
there were no statistical comparisons of complication rates;11
however, the device group had no postoperative complica-
tions, whereas the trabeculectomy group had a high compli-
cation rate: hyphema (40%), shallow anterior chamber (30%),
and choroidal detachment (15%). Of the remaining four non-
randomized studies, one reported one complication rate that
was significantly different between groups (choroidal effu-
sion, favoring the EX-PRESS device).20 The rest of the compli-
cations had no significant differences between groups.15,21,30
None of the randomized trials reported any significant
differences in any of the subsequent interventions between
groups,4,7,8 although one of the two studies did report a
significantly lower overall surgical intervention rate.4 Two15,20
of the five non-randomized studies11,21,30 reported signifi-
cantly higher laser suture lysis procedures in the device group.
The suture lysis rates reported with EX-PRESS device im-
plantation were highly variable across studies, ranging from
0% to 51%, and one study reported that patients receiving the
EX-PRESS device received a mean of 2.2 suture lysis pro-
cedures each. These laser suture lysis rates are highly
dependent upon both surgical technique and surgeon phi-
losophy, which may explain the variability across trials.
Of the seven studies with visual acuity results, two non-
randomized studies showed a significant advantage for the
device group in the early postoperative period.15,30 The
remaining studies, including the two of the four randomized
trials, demonstrated no significant difference.4,7,20 One of the
s u r v e y o f o p h t h a lmo l o g y 6 0 ( 2 0 1 5 ) 3 2 7e3 4 5344randomized clinical trial followed patients over 1 year and
reported a significant improvement in recovery from loss of
visual acuity in the EX-PRESS device group as compared with
the trabeculectomy group1,33 and another study reported
return of visual acuity to baseline within 1 month of surgery
with the EX-PRESS device, compared with 3 months with
trabeculectomy.24 Although current evidence is inconclusive
as to whether visual recovery might be faster with the
EX-PRESS device, the possibility is worthy of further study.
We have examined all the relevant and available clinical
evidence with the EX-PRESS device, but this review does have
a number of limitations. Because we did not want to exclude
any studies that might provide some insight into the use of
this device, we evaluated studies that were not rigorously
controlled. Only 4 of the 9 comparative studies were ran-
domized. Furthermore, surgical techniques for both trabecu-
lectomy and the EX-PRESS device implantation varied.
Additionally, the methods used and analyses performed
studies were not uniform. As an example, these eight studies
contained four different thresholds defining success rates.
Finally, the lack of uniformity in study design, definitions of
success, and reporting of efficacy endpoints and postoperative
complications of surgery in glaucoma clinical trials, as
summarized in the Guidelines on Design and Reporting of
Glaucoma Surgical Trials, make it difficult to draw firm
conclusions regarding the relative efficacy and safety of the
EX-PRESS device compared with trabeculectomy.28,32 It would
also be helpful to have data that allow an economic evalua-
tion. As the Guidelines on Design and Reporting of Glaucoma
Surgical Trials acknowledge, any such analysis will depend on
the cost structures in the jurisdiction in which the analysis is
conducted. Inclusion of the EX-PRESS device in a procedure
compared with trabeculectomy alone increases costs to the
system (payor) or decreases any profit (provider), assuming all
other consumables remain the same. In one analysis per-
formed in the United States, the average difference between
total disposable item acquisition and Medicare payment per
case was $1,834.50 for trabeculectomy and $763.30 for the
EX-PRESS device. The remaining difference represents the
funds available to the facility to support staff, equipment, and
the other goods and services required to provide the surgical
services. The difference would vary by practice setting and
does not account for variations in the cost of postoperative
care or societal costs during the patient’s visual recovery.32
Another randomized controlled study that compared the
1-year cost difference between the two procedures in 43 par-
ticipants (n ¼ 23 for EX-PRESS and n ¼ 20 for trabeculectomy),
calculated that the operative cost of the EX-PRESS device
was $956 more than trabeculectomy. Postoperative costs
(glaucoma medications, follow-up visits, and additional pro-
cedures) were similar for the two procedures.25 In other re-
gions of the world the costs and these calculations may vary
significantly. For example, in the United States, where one of
the authors practices, the EX-PRESS is approved for use in
patients where medical and conventional surgical treatments
have failed. In this system Medicare reimburses the surgeon
$1,752 for a trabeculectomy with scarring from previous
ocular surgery (CPT code 66,172) and $1,214 for insertion of
an anterior drainage device, without extraocular reservoir
(EX-PRESS); external approach (CPT code 66,183). Theselimitations and regional cost and health care reimbursement
differences make it difficult to draw firm conclusions
regarding the relative efficacy, safety, and cost-effectiveness
of inclusion of the EX-PRESS device compared with trabecu-
lectomy alone, but there is added cost from the use of a device.
Nonetheless, prospective and retrospective single-surgeon
reports of experience with the EX-PRESS device provide a
profile of a glaucoma surgical device producing IOP reduction
that is at least as good as trabeculectomy and may have some
possible advantages. Postoperative complication rates are
similar and sometimes lower with EX-PRESS implantation
compared with trabeculectomy. Some specific complications
may differ between trabeculectomy (e.g., iris bleeding, vitre-
ous prolapse) and EX-PRESS (device malposition or disloca-
tion) because of the technical differences between the
procedures. Subsequent interventions are similar with both
approaches, except for laser suture lysis, which may be more
frequently required with the EX-PRESS device. The strength of
evidence for the safety and efficacy of the EX-PRESS device is
limited as a result of the design of these studies and the
challenges encountered by attempting to compare outcomes
among divergent studies using varying techniques and
differing definitions of success. Clearly, the potential advan-
tage the EX-PRESS device may provide over trabeculectomy
should be considered incremental rather than revolutionary.
For select patients, eliminating peripheral iridectomy and the
need for tissue removal and standardizing the outlet from the
anterior chamber offers a safety advantage. Additional issues
of interest include cost effectiveness and utility of the device,
but these are community-specific, requiring that each health
system address such questions independently. Another issue
is the potential effect of the EX-PRESS device on the corneal
endothelium, but only long-term longitudinal studies can
address this.5. Conclusion
The current data show similar efficacy results between
EX-PRESS implantation and trabeculectomy, with some re-
ports of diminished complications. Longer-term, multicenter,
prospective studies would clarify whether the EX-PRESS
glaucoma filtration device offers superior safety and similar
efficacy compared with trabeculectomy for a broader popu-
lation of surgeons and patients.6. Method of literature search
We systematically reviewed the literature to determine the
relative efficacy and safety of the EX-PRESS glaucoma filtra-
tion device compared with trabeculectomy. We conducted a
PubMed.gov search using the terms EX-PRESS and glaucoma to
identify publications through February 2014 (no lower time
limit imposed) of prospective and retrospective clinical
studies with the EX-PRESS device in primarily on-label set-
tings. Types of studies excluded were nonclinical studies, re-
view articles, case reports, letters to the editor, and articles
focused on surgical technique. Additionally, those studies
describing full-thickness subconjunctival EX-PRESS device
s u r v e y o f o p h t h a lm o l o g y 6 0 ( 2 0 1 5 ) 3 2 7e3 4 5 345implantation were excluded, because scleral flap implanta-
tion is now the standard method of implantation. Articles not
available in English, those for which the EX-PRESS device was
not the focus of the clinical study, and those performed by
inexperienced surgeons (i.e., residents) were also excluded.7. Disclosures
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